Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$1.3 million.

  • Cartesian Therapeutics' Cash from Investing Activities rose 7915.79% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 18112.11%. This contributed to the annual value of -$8.7 million for FY2024, which is 12525.93% down from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Cash from Investing Activities is -$1.3 million, which was up 7915.79% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Cash from Investing Activities peaked at $28.1 million during Q1 2023, and registered a low of -$29.9 million during Q3 2022.
  • In the last 5 years, Cartesian Therapeutics' Cash from Investing Activities had a median value of -$838500.0 in 2024 and averaged -$624277.8.
  • Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Cash from Investing Activities was 595662.65% (2021), while the steepest drop was 1652592.59% (2021).
  • Over the past 5 years, Cartesian Therapeutics' Cash from Investing Activities (Quarter) stood at $9.7 million in 2021, then tumbled by 43.54% to $5.5 million in 2022, then rose by 18.36% to $6.5 million in 2023, then tumbled by 105.45% to -$354000.0 in 2024, then crashed by 264.97% to -$1.3 million in 2025.
  • Its Cash from Investing Activities stands at -$1.3 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.1 million for Q1 2025.